3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
pembrolizumab
7
Ipilimumab
7
Nivolumab
5
Melphalan
5
Dacarbazine
3
tebentafusp
2
sotrastaurin
2
binimetinib
2
Pemetrexed
2
Crizotinib
2
ADI PEG20
2
utomilumab
1
trametinib
1
tocilizumab
1
siremadlin
1
ruxolitinib
1
relatlimab
1
obinutuzumab
1
fludarabine phosphate
1
fludarabine
1
cemiplimab
1
avelumab
1
Watchful Waiting
1
Toll-Like Receptor 1
1
Standard of Care
1
Solutions
1
Rose Bengal
1
Protein Kinase C
1
Polyethylene Glycols
1
Opdualag
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uveal Melanoma
×
Standard of Care
×
Clear all
NCT05266430
2023-08-09
IL
Aura Biosciences
Terminated
2 enrolled